Attached files
| file | filename |
|---|---|
| 10-K - 10-K - AMERISOURCEBERGEN CORP | abc10-kxseptember302016.htm |
| EX-32 - EXHIBIT 32 - AMERISOURCEBERGEN CORP | exhibit32section1350certif.htm |
| EX-31.2 - EXHIBIT 31.2 - AMERISOURCEBERGEN CORP | exhibit312rule13a-14a15dx1.htm |
| EX-31.1 - EXHIBIT 31.1 - AMERISOURCEBERGEN CORP | exhibit311rule13a-14a15dx1.htm |
| EX-23 - EXHIBIT 23 - AMERISOURCEBERGEN CORP | exhibit23consentofindepend.htm |
| EX-21 - EXHIBIT 21 - AMERISOURCEBERGEN CORP | exhibit21subsidiariesofthe.htm |
Exhibit 12
AmerisourceBergen Corporation
Computation of Ratio of Earnings to Fixed Charges
Fiscal Year Ended September 30, | ||||||||||||||||||||
(in thousands, except ratios) | 2016 | 2015 | 2014 | 2013 | 2012 | |||||||||||||||
Determination of earnings: | (As Revised) | (As Revised) | (As Revised) | (As Revised) | ||||||||||||||||
Income from continuing operations before income taxes | $ | 1,390,910 | $ | 268,964 | $ | 669,863 | $ | 822,032 | $ | 1,214,578 | ||||||||||
Add: | ||||||||||||||||||||
(Gain) loss on equity investments | (582 | ) | 30,833 | 172 | 113 | 380 | ||||||||||||||
Fixed charges (excluding capitalized interest) | 157,666 | 123,818 | 95,760 | 92,352 | 108,384 | |||||||||||||||
Amortization of capitalized interest | 1,676 | 1,676 | 1,676 | 1,635 | 1,443 | |||||||||||||||
Total earnings available for fixed charges | $ | 1,549,670 | $ | 425,291 | $ | 767,471 | $ | 916,132 | $ | 1,324,785 | ||||||||||
Fixed charges: | ||||||||||||||||||||
Interest expense | $ | 144,349 | $ | 112,021 | $ | 84,475 | $ | 81,477 | $ | 100,253 | ||||||||||
Capitalized interest | — | — | — | — | 504 | |||||||||||||||
Estimated interest portion of rent expense | 13,317 | 11,797 | 11,285 | 10,875 | 8,131 | |||||||||||||||
Total fixed charges | $ | 157,666 | $ | 123,818 | $ | 95,760 | $ | 92,352 | $ | 108,888 | ||||||||||
Ratio of earnings to fixed charges 1 | 9.8 | 3.4 | 8.0 | 9.9 | 12.2 | |||||||||||||||
____________________
1 For purposes of computing the above ratios:
• | Earnings include Warrants expense, a non-cash expense, of $140.3 million, $912.7 million, $422.7 million, and $90.1 million in the fiscal years ended September 30, 2016, 2015, 2014, and 2013, respectively. |
• | (Gain) loss on equity investments includes an impairment charge of $30.6 million in fiscal 2015 related to the Company's minority interest in a pharmaceutical wholesaler in Brazil. There was no such impairment charge recorded in the fiscal years ended September 30, 2016, 2014, 2013, and 2012, respectively. |